Amanda Grimes 2013 Arizona Bioscience Educator of the Year
Some of the most important messages AZBio received about Mrs. Grimes work came from students she has helped to inspire: “She has taught each and every one of us that science can be fun too. A lot of people get stuck on the math but she opens it up to where it’s interesting and reels you in like a fish on a hook.” “As a high school graduate I can look back upon my time as a student and pick out a few teachers who have influenced my life and helped me flourish as a student. The number one teacher on that list is Mrs. Grimes. Having had Mrs. Grimes as a teacher for two years has helped me make connections, plan my future, and given me opportunities no other teachers have ever attempted. Without Mrs. Grimes I never would have joined the Biotech Academy at Mesa High School, meaning I would never have discovered my love for science and research.” “One of Mrs. Grimes’ most admirable qualities would be her patience with her students. Mrs. Grimes’ never ending patience and abundant respect for her students makes her an extraordinary teacher and mentor, always willing to answer questions or stay late to help. She does everything she can to ensure her students have every opportunity to advance their knowledge and experience beyond that of a typical high school student.” “Mrs. Grimes always encourages her students to excel in every aspect of their life, whether that be academics, community service, or extracurricular activities. I, and many of my peers, admire Mrs. Grimes for her dedication to her career and her students and wouldn’t be where we are if it weren't for her model of excellence.” “She has opened my eyes to the world of biotechnology and I am enthralled to be a part of it, I will not go quietly in this field.” The Biotechnology Academy (Mesa Public Schools) is a four-year program that provides freshmen-senior high students with experience in biotechnology theory and techniques, and prepares them for continuing education in Biotechnology Degree programs or related fields.
Company Presentation - Kulira Technologies
Kulira Technologies is an advanced biomedical engineering company that designs solutions for surgical oncology using state-of-the-art biomaterials. President and CEO, Xenia Kachur, shares where they've been and where they are going at AZBio Expo 2013.
Arizona Pioneer Thomas M. Grogan, MD
Thomas M. Grogan, M.D., Founder of Ventana and SVP, Medical Affairs of Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, receives the AZBio Pioneer Award for Lifetime Achievement at the 2013 AZBio Awards on October 10, 2013. Dr. Grogan was a pathologist and professor at the University of Arizona when in the mid 1980’s he and a small team set out to challenge the limitations of the then current standards and processes for cancer pathology. What was to become the company’s first digital pathology instrument evolved from Grogan’s notes on a yellow pad into the BenchMark IHC/ISH staining platforms. Under Grogan’s leadership, Ventana was founded in 1987, went public in 1996, and was acquired by Roche for $3.4 billion in 2008. Over the last 25 years, Ventana has grown to become a global leader in developing and manufacturing tissue-based diagnostic instruments and tests focused on the detection of cancer. Ventana employees continue to pursue the same deeply rooted mission of innovating diagnostic testing and enabling personalized healthcare to improve the lives of all patients afflicted with cancer worldwide. Dr. Grogan has made it his personal mission to make life better for the millions of patients who battle cancer each day. His passion and dedication are infectious and has spread across the company that he and his team built. Through their efforts they have revolutionized the field of cancer diagnostics and are pioneering new roads in the field of personalized healthcare.”
John W. Lewis, Mayor of the Town of Gibert - 2013 Public Service Award Honoree
John W. Lewis, Mayor of the Town of Gilbert,was recognized with the 2013 AZBio Public Service Award from the Arizona Bioindustry Association in recognition for his vision and leadership in creating a health and bioscience innovation strategic focus in America’s largest town. Under Mayor Lewis’s leadership, Gilbert is attracting global leaders, spurring economic development, and creating quality and high-wage life science jobs.
The Greener Side of Bio
AZBio Board Chair and Co-Founder of Algae Biosciences, Glen Galster , moderates this panel discussion on the state of Arizona's green bio industry amd whwere it's going with Leif P. Christoffersen , Director of Biomass Integration, Yulex Corporation . Leif is responsible for advancing Yulex’s energy, efficiency and biomass initiatives. Prior to Yulex, Christoffersen played a key role in establishing the E.O. Wilson Biodiversity Foundation (EOWBF) with whom he maintains an active advisory role. He also spent over five years at the Diversa Corporation (Verenium Corporation and BP Biofuels), where he managed bioprospecting collaborations, as well as managed Diversa’s grants program, coordinated their scientific advisory board, and supported their international business development efforts. Christoffersen has also served as a climate change adviser to the Executive Director of UNEP at COP1 and COP2 of the Climate Change Convention (UNFCCC). At the start of his career, he worked with subsistence farmers in Costa Rica and Kenya to support and promote agroforestry practices, which included setting up exportation of organic produce. Christoffersen holds a degree from Hobart College (BA, Economics) and the University of California, San Diego (MBA, Rady School of Management). Ben Cloud , President and CEO, Phyco Biosciences, Inc ., brings over 30 years of experience as a farmer and farmland developer with operations in Arizona and Southern California. His significant experience in production agriculture including drip-micro irrigation systems and design, cropping systems, processing and marketing have contributed to the development of the Phyco production platform and business approach (To learn more, click here .) and Josh Hottenstein of the Cleantech Open
W.L. Gore and Associaties, Inc. the 2013 Arizona Bioscience Company of the Year
W.L. Gore & Associates was honored at the 2013 AZBio Awards as the Arizona Bioscience Company of the Year by the Arizona Bioindustry Association in recognition of the development of the extensive Gore Medical family of products including vascular grafts, endovascular and interventional devices, and surgical meshes by its world class team of innovators in Flagstaff and Phoenix. In this video you will learn about Gore and also gain insights on what we need to do together to continue our Arizona Bioscience Industry growth from Gore's Kurt Long.
David S Alberts AZBio Pioneer
David S. Alberts, MD. Throughout his career, Dr. Alberts has focused on translational cancer prevention and treatment research. The emphasis of his laboratory-based and clinical research has been on the chemoprevention and treatment of such pervasive and potentially deadly diseases as cancers of the breast, colon, ovary, and skin. He has been the UA Cancer Center’s director since 2005. Under Dr. Alberts’ leadership the extensive research portfolio of The University of Arizona Cancer Center includes more than $60 million in annual research funding, including four large NCI interdisciplinary programs, and two Special Programs of Research Excellence, one in gastrointestinal cancers and one in lymphoma. Clinically, Dr. Alberts pioneered new treatments for advanced ovarian cancers, including in vitro tumor cell chemosensitivity testing for personalized medicine strategies, intraperitoneal chemotherapy , and maintenance chemotherapy. Presently, Dr. Alberts helps to coordinate Phase I and II and pharmacokinetic drug studies at The University of Arizona Cancer Center for molecularly-targeted chemopreventive agents. His laboratory research is concentrated on the evaluation of new surrogate endpoint biomarkers for cancer prevention trials with a special focus on precursor lesions for bladder, breast, colon, cervical, endometrial, ovarian, prostate, and skin cancers, using quantitative histopathology (i.e. karyometric) approaches. His NCI funded drug and diagnostics research has resulted in more than two dozen patents and the co-founding of five Arizona pharmaceutical and biotechnology companies.
2012 AZBio Fast Lane Award Winner - Ulthera
Beauty and Growth – Ulthera, Inc Ulthera’s mission is to work with physicians to provide therapeutic ultrasound to improve the appearance and health of patients worldwide. The company is not only defined by its proprietary technology, but also its people. Ulthera’s team consists of experts in their respective fields who are aligned by the strength of the company’s mission and its leadership. Ulthera was founded in 2004 to leverage seven years of prior scientific research in therapeutic ultrasound for aesthetic and medical applications. In 2009, the Ulthera® System received FDA approval in the United States and is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. The first application for Ultherapy® – the procedure enabled by the System – is a non-invasive treatment of the face to achieve a brow lift. Ulthera’s robust scientific foundation and relentless pursuit of superior clinical outcomes have resulted in the rapid global uptake of the Ulthera platform. As Ulthera continues to develop and provide more applications for its platform, the company also remains committed to bringing value to physicians and their patients. In 2006, Matt Likens was hired as President and CEO of Ulthera by founder and owner Michael Slayton, Ph. D, with the expectation of obtaining FDA approval for Ulthera’s product and service (known as Ultherapy) within three months. Less than two years into his tenure at Ulthera, Matt found himself navigating this venture capital backed start-up though the worst economic downtown since the Great Depression. The Company also found itself facing an increasing skeptical and less commercially friendly US Food and Drug Administration (FDA) regime. With both of these risks significantly threatening the Company’s viability, Matt decided to change the Company’s regulatory pathway and focus by obtaining CE Mark from the European Union prior to obtaining FDA clearance. If this bet paid off, Ulthera’s regulatory runway would be significantly reduced and the Company would be able to generate sales in the European market. These revenues would also allow the Company to lessen the need to obtain additional venture capital financing thus reducing additional dilution to the Company’s current shareholders. While risky, the core of this decision was based on the multinational experience Likens attained at Baxter and his general entrepreneurial nature. The bet ultimately paid off. Today, Ulthera is a global, growth-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. More than 1,000 Ulthera Systems have been sold globally while treatments performed using the System have surpassed 100,000.
Washington Update from Congressman Paul Gosar DDS
Congressman Paul Gosar (AZ-4th District) is a health care provider and small business owner who is focused on bringing jobs back to the district, reforming health care, reining in government spending and ensuring that his constituents are involved in the solution process. Congressman Paul Gosar serves on the House Committee on Oversight and Government Reform including as t he Vice Chairman of the House Subcommittee on Energy Policy, Health Care, and Entitlements which has oversight over federal health care policy, food and drug safety, energy policy, solvency of federal entitlement programs. He also serves on the Subcommittee on Economic Growth, Job Creation, and Regulatory Affairs which has oversight jurisdiction regulatory affairs, impediments to economic growth and job creation, monetary policy, banking, infrastructure, and tax policy as well as the Subcommittee on National Security which has Oversight jurisdiction over national security, homeland security, foreign operations, immigration, emergency management, and criminal justice.
Raymond L. Woosley, MD, PhD - 2012 AZBio Pioneer
Raymond L. Woosley earned a Ph.D. in Pharmacology from the University of Louisville and an M.D. from the University of Miami. He began his career as the first scientist in the US operations for Glaxo, now known as GlaxoSmithKline. Dr. Woosley specialized in Internal Medicine and Clinical Pharmacology at Vanderbilt University where he rose to the rank of Professor of Medicine. At Georgetown University he served as Chairman of the Department of Pharmacology and in 2000 was appointed Associate Dean for Clinical Research. In 2001 he became Vice President for Health Sciences at the University of Arizona and Dean of the College of Medicine. In January of 2005 he assumed the position of President of The Critical Path Institute (C-Path), a non-profit corporation formed by the Food and Drug Administration, SRI, International and the University of Arizona to accelerate the development of safe innovative medicines. Since 1999, he has directed one of seven federally-funded (Agency for Healthcare Research and Quality) Centers for Education and Research on Therapeutics (CERT).Under Dr. Woosley’s leadership, C-Path (the Critical Path Institute) orchestrated the acceleration of medical product development through a unique collaborative process among industry, academia, and the FDA. Our collaborations among 6 global consortia, 1000+scientists, and 41 companies has already produced these notable successes: First preclinical safety biomarkers (7) qualified by the FDA, EMA, and PMDA (the Japanese counterpart) First CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard First and largest open database of CDISC aggregated clinical trial data for Alzheimer’s disease (6,100 patients and 22 clinical trials) Read more First drug-disease trial model & clinical trial simulation tool submitted and under review by the FDA First imaging biomarker for trial enrichment qualified by the EMA Dr. Woosley’s research has investigated the basic and clinical pharmacology of drugs for the treatment of arrhythmias and the cardiac toxicity of drugs, and has been published in over 260 publications. His research discovered the mechanism of the toxicity of the antihistamine Seldane®. He is the recipient of the Rawls-Palmer Award from the American Society of Clinical Pharmacology and Therapeutics for his contributions to medicine and the FDA Commissioner’s Special Citation for his work to advise the agency on the toxicity of dietary supplements containing ephedra. Dr. Woosley is a Past-President of the Association for Medical School Pharmacology and the American Society for Clinical Pharmacology and Therapeutics. He has served on numerous boards including the US Pharmacopeia. He is a member of the Biodesign Institute at Arizona State University. As a member of the University of Arizona’s Sarver Heart Center and Bio5 Institute, he conducts research on the prevention of adverse drug interactions.